CMAJ • March 13, 2007; 176 (6). doi:10.1503/cmaj.1060242.
© 2007 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Porath, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Porath, A.
Related Collections
Right arrow Drugs: gastrointestinal system
Right arrow Clostridium difficile

Letters

Possible patient overlap in studies

Adam Porath

Pharmacy Practice Resident, Department of Pharmacy, Renown Regional Medical Center, Reno, Nev.

I read with great interest the article by Sandra Dial and colleagues, in which they reported an increased risk of Clostridium difficile-associated disease with exposure to proton pump inhibitors.1 The cases in this study were recorded in the United Kingdom General Practice Research Database (GPRD) between Jan. 1, 1994, and Dec. 31, 2004. The authors claim that there was no overlap between the cases in this study and those in a study they published previously.2 Interestingly, in the previous study conducted by Dial and colleagues, data were derived from the same database over the same time period.2 The cases included in that study were instances of a first occurrence of C. difficile-associated disease defined on the basis of a positive C. difficile toxin assay or a clinical diagnosis by a general practitioner. How is it possible that the patients in the current study are not the same ones who were previously studied? It seems very likely that any of the patients treated with oral vancomycin who were included in the current study either would have had a positive C. difficile toxin result or would have received a clinical diagnosis of C. difficile-associated disease during the study period.

REFERENCES

  1. Dial S, Delaney JAC, Scheider V, et al. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006;175(7):745-8.[Abstract/Free Full Text]
  2. Dial S, Delaney JAC, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-95.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Porath, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Porath, A.
Related Collections
Right arrow Drugs: gastrointestinal system
Right arrow Clostridium difficile